(TECH) Bio-Techne - Ratings and Ratios
Reagents, Instruments, Services, Diagnostics, Proteomics
TECH EPS (Earnings per Share)
TECH Revenue
Description: TECH Bio-Techne
Bio-Techne Corporation is a life science company that develops, manufactures, and sells reagents, instruments, and services for research, diagnostics, and bioprocessing markets globally. The company operates through two segments: Protein Sciences and Diagnostics and Genomics, offering a range of products, including biological reagents, diagnostic assays, and analytical tools.
From a business perspective, Bio-Technes revenue streams are diversified across various markets, including life science research, diagnostics, and bioprocessing. The companys Protein Sciences segment is a key player in the life science research market, offering a range of products, including cytokines, antibodies, and proteomic analytical tools. The Diagnostics and Genomics segment is focused on developing and manufacturing diagnostic products, including controls, calibrators, and diagnostic assays, for regulated diagnostics markets.
Some key performance indicators (KPIs) to evaluate Bio-Technes performance include revenue growth, gross margin, and research and development (R&D) expenses as a percentage of revenue. With a market capitalization of $8.53 billion, Bio-Technes revenue growth has been driven by its strategic partnerships, such as the one with ALZpath, Inc., to accelerate breakthroughs in neurodegenerative disease research and treatment. The companys gross margin is likely to be influenced by its product mix, pricing, and manufacturing efficiency.
In terms of valuation, Bio-Technes price-to-earnings (P/E) ratio of 65.55 suggests that the stock may be relatively expensive compared to its earnings. However, the forward P/E ratio of 24.75 indicates that the companys earnings are expected to grow in the future. Return on equity (RoE) of 6.34% is a metric that can be used to evaluate the companys profitability. To further assess the companys valuation, metrics such as enterprise value-to-EBITDA (EV/EBITDA) and dividend yield (if applicable) can be considered.
Overall, Bio-Techne Corporation is a well-established player in the life science industry, with a diversified product portfolio and a strong presence in the research and diagnostics markets. Its strategic partnerships and commitment to R&D are likely to drive future growth and innovation.
TECH Stock Overview
| Market Cap in USD | 8,014m |
| Sub-Industry | Life Sciences Tools & Services |
| IPO / Inception | 1989-02-09 |
TECH Stock Ratings
| Growth Rating | -64.0% |
| Fundamental | 63.4% |
| Dividend Rating | 29.6% |
| Return 12m vs S&P 500 | -41.7% |
| Analyst Rating | 4.13 of 5 |
TECH Dividends
| Dividend Yield 12m | 0.57% |
| Yield on Cost 5y | 0.55% |
| Annual Growth 5y | 0.00% |
| Payout Consistency | 95.3% |
| Payout Ratio | 16.6% |
TECH Growth Ratios
| Growth Correlation 3m | 24.5% |
| Growth Correlation 12m | -78.4% |
| Growth Correlation 5y | -69% |
| CAGR 5y | -9.49% |
| CAGR/Max DD 3y | -0.20 |
| CAGR/Mean DD 3y | -0.55 |
| Sharpe Ratio 12m | -0.40 |
| Alpha | 0.05 |
| Beta | 0.657 |
| Volatility | 37.61% |
| Current Volume | 1647.1k |
| Average Volume 20d | 1872.9k |
| Stop Loss | 50.7 (-4.3%) |
| Signal | -1.14 |
Piotroski VR‑10 (Strict, 0-10) 7.5
| Net Income (73.4m TTM) > 0 and > 6% of Revenue (6% = 73.2m TTM) |
| FCFTA 0.10 (>2.0%) and ΔFCFTA 1.64pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 35.46% (prev 39.52%; Δ -4.06pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.11 (>3.0%) and CFO 287.6m > Net Income 73.4m (YES >=105%, WARN >=100%) |
| Net Debt (281.9m) to EBITDA (223.1m) ratio: 1.26 <= 3.0 (WARN <= 3.5) |
| Current Ratio 3.46 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (154.9m) change vs 12m ago -3.57% (target <= -2.0% for YES) |
| Gross Margin 64.80% (prev 66.60%; Δ -1.80pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 45.42% (prev 41.20%; Δ 4.21pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 13.30 (EBITDA TTM 223.1m / Interest Expense TTM 8.51m) >= 6 (WARN >= 3) |
Altman Z'' 4.41
| (A) 0.17 = (Total Current Assets 608.3m - Total Current Liabilities 175.8m) / Total Assets 2.56b |
| (B) 0.42 = Retained Earnings (Balance) 1.07b / Total Assets 2.56b |
| (C) 0.04 = EBIT TTM 113.2m / Avg Total Assets 2.69b |
| (D) 1.58 = Book Value of Equity 1.01b / Total Liabilities 639.1m |
| Total Rating: 4.41 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 63.40
| 1. Piotroski 7.50pt = 2.50 |
| 2. FCF Yield 3.12% = 1.56 |
| 3. FCF Margin 21.03% = 5.26 |
| 4. Debt/Equity 0.19 = 2.48 |
| 5. Debt/Ebitda 1.61 = 0.75 |
| 6. ROIC - WACC (= -4.48)% = -5.60 |
| 7. RoE 3.60% = 0.30 |
| 8. Rev. Trend 74.12% = 5.56 |
| 9. EPS Trend 11.75% = 0.59 |
What is the price of TECH shares?
Over the past week, the price has changed by -0.41%, over one month by -0.56%, over three months by +5.86% and over the past year by -30.37%.
Is Bio-Techne a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of TECH is around 41.66 USD . This means that TECH is currently overvalued and has a potential downside of -21.38%.
Is TECH a buy, sell or hold?
- Strong Buy: 7
- Buy: 3
- Hold: 5
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the TECH price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 66.2 | 25% |
| Analysts Target Price | 66.2 | 25% |
| ValueRay Target Price | 46.3 | -12.7% |
Last update: 2025-09-19 04:43
TECH Fundamental Data Overview
CCE Cash And Equivalents = 162.2m USD (Cash And Short Term Investments, last quarter)
P/E Trailing = 112.0
P/E Forward = 25.3165
P/S = 6.5707
P/B = 4.1976
P/EG = 0.691
Beta = 1.466
Revenue TTM = 1.22b USD
EBIT TTM = 113.2m USD
EBITDA TTM = 223.1m USD
Long Term Debt = 346.0m USD (from longTermDebt, last quarter)
Short Term Debt = 14.1m USD (from shortTermDebt, last quarter)
Debt = 360.1m USD (Calculated: Short Term 14.1m + Long Term 346.0m)
Net Debt = 281.9m USD (from netDebt column, last quarter)
Enterprise Value = 8.21b USD (8.01b + Debt 360.1m - CCE 162.2m)
Interest Coverage Ratio = 13.30 (Ebit TTM 113.2m / Interest Expense TTM 8.51m)
FCF Yield = 3.12% (FCF TTM 256.6m / Enterprise Value 8.21b)
FCF Margin = 21.03% (FCF TTM 256.6m / Revenue TTM 1.22b)
Net Margin = 6.02% (Net Income TTM 73.4m / Revenue TTM 1.22b)
Gross Margin = 64.80% ((Revenue TTM 1.22b - Cost of Revenue TTM 429.4m) / Revenue TTM)
Tobins Q-Ratio = 8.15 (Enterprise Value 8.21b / Book Value Of Equity 1.01b)
Interest Expense / Debt = 0.60% (Interest Expense 2.18m / Debt 360.1m)
Taxrate = 25.45% (25.1m / 98.5m)
NOPAT = 84.4m (EBIT 113.2m * (1 - 25.45%))
Current Ratio = 3.46 (Total Current Assets 608.3m / Total Current Liabilities 175.8m)
Debt / Equity = 0.19 (Debt 360.1m / last Quarter total Stockholder Equity 1.92b)
Debt / EBITDA = 1.61 (Net Debt 281.9m / EBITDA 223.1m)
Debt / FCF = 1.40 (Debt 360.1m / FCF TTM 256.6m)
Total Stockholder Equity = 2.04b (last 4 quarters mean)
RoA = 2.87% (Net Income 73.4m, Total Assets 2.56b )
RoE = 3.60% (Net Income TTM 73.4m / Total Stockholder Equity 2.04b)
RoCE = 4.75% (Ebit 113.2m / (Equity 2.04b + L.T.Debt 346.0m))
RoIC = 3.58% (NOPAT 84.4m / Invested Capital 2.36b)
WACC = 8.06% (E(8.01b)/V(8.37b) * Re(8.40%)) + (D(360.1m)/V(8.37b) * Rd(0.60%) * (1-Tc(0.25)))
Shares Correlation 3-Years: -60.61 | Cagr: -0.42%
Discount Rate = 8.40% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 76.12% ; FCFE base≈248.4m ; Y1≈234.8m ; Y5≈222.6m
Fair Price DCF = 23.96 (DCF Value 3.73b / Shares Outstanding 155.5m; 5y FCF grow -7.08% → 3.0% )
EPS Correlation: 11.75 | EPS CAGR: 6.13% | SUE: 1.08 | # QB: 2
Revenue Correlation: 74.12 | Revenue CAGR: 6.05% | SUE: 0.0 | # QB: 0
Additional Sources for TECH Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle